ZBNA
ACRS icon

Zions Bancorporation, National Association’s Aclaris Therapeutics ACRS Stock Holding History

Zions Bancorporation, National Association’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$825 Buy
+156
New +$696 ﹤0.01% 1461

Other funds holding ACRS

TBWA
Three Bridge Wealth Advisors Los Altos, California $399M AUM 18.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
CFS
CRA Financial Services Northfield, New Jersey $868M AUM 25.66% 1-Year Est. Return

Zions Bancorporation, National Association's ACRS Position: Q2 2026 in Review

Zions Bancorporation, National Association opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 156 shares worth $825. The stake represents ﹤0.01% of the portfolio and ranks #1461 among its holdings.

22 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Zions Bancorporation, National Association held 156 shares of Aclaris Therapeutics worth $825 as of Q2 2026.
  • Aclaris Therapeutics was a new Zions Bancorporation, National Association position in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Zions Bancorporation, National Association's portfolio in Q2 2026, its #1461 holding.
  • 22 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Zions Bancorporation, National Association's 13F filing for Q2 2026, filed 31 Jul 2026.